Literature DB >> 32166677

Application of Paclitaxel-loaded EGFR Peptide-conjugated Magnetic Polymeric Liposomes for Liver Cancer Therapy.

Zhen-Lv Lin1, Jian Ding2, Guo-Ping Sun3, Dan Li4, Shan-Shan He5, Xiao-Fei Liang6, Xun-Ru Huang5, Jie Xie1,7.   

Abstract

Developing the methodologies that allow for safe and effective delivery of therapeutic drugs to target sites is a very important research area in cancer therapy. In this study, polyethylene glycol (PEG)-coated magnetic polymeric liposome (MPL) nanoparticles (NPs) assembled from octadecyl quaternized carboxymethyl chitosan (OQC), PEGylated OQC, cholesterol, and magnetic NPs, and functionalized with epithelial growth factor receptor (EGFR) peptide, were successfully prepared for in-vivo liver targeting. The two-step liver targeting strategy, based on both magnetic force and EGFR peptide conjugation, was evaluated in a subcutaneous hepatocellular carcinoma model of nude mouse. The results showed that EGFR-conjugated MPLs not only accumulated in the liver by magnetic force, but could also diffuse into tumor cells as a result of EGFR targeting. In addition, paclitaxel (PTX) was incorporated into small EGFR-conjugated MPLs (102.0±0.7 nm), resulting in spherical particles with high drug encapsulation efficiency (>90%). The use of the magnetic targeting for enhancing the transport of PTX-loaded EGFR-conjugated MPLs to the tumor site was further confirmed by detecting PTX levels. In conclusion, PTX-loaded EGFR-conjugated MPLs could potentially be used as an effective drug delivery system for targeted liver cancer therapy.

Entities:  

Keywords:  drug delivery; liver cancer; magnetic nanoparticles; quaternized chitosan; targeted therapy

Mesh:

Substances:

Year:  2020        PMID: 32166677     DOI: 10.1007/s11596-020-2158-4

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  40 in total

1.  Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma.

Authors:  Mona A Abdelmoneem; Mazen Mahmoud; Amira Zaky; Maged W Helmy; Marwa Sallam; Jia-You Fang; Kadria A Elkhodairy; Ahmed O Elzoghby
Journal:  J Control Release       Date:  2018-08-20       Impact factor: 9.776

Review 2.  Nanomedicine in management of hepatocellular carcinoma: Challenges and opportunities.

Authors:  Nourhan K Mohamed; Mostafa A Hamad; Mohamed Z E Hafez; Karen L Wooley; Mahmoud Elsabahy
Journal:  Int J Cancer       Date:  2016-12-02       Impact factor: 7.396

Review 3.  Targeted therapies for hepatocellular carcinoma.

Authors:  Augusto Villanueva; Josep M Llovet
Journal:  Gastroenterology       Date:  2011-03-13       Impact factor: 22.682

Review 4.  New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.

Authors:  Alberto A Gabizon; Yogita Patil; Ninh M La-Beck
Journal:  Drug Resist Updat       Date:  2016-10-29       Impact factor: 18.500

5.  Design and biological activity of epidermal growth factor receptor-targeted peptide doxorubicin conjugate.

Authors:  Mingliang Fan; Danbo Yang; Xiaofei Liang; Junping Ao; Zonghai Li; Hongyang Wang; Bizhi Shi
Journal:  Biomed Pharmacother       Date:  2015-02-07       Impact factor: 6.529

6.  pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma.

Authors:  Daishun Ling; Hongping Xia; Wooram Park; Michael J Hackett; Changyeong Song; Kun Na; Kam Man Hui; Taeghwan Hyeon
Journal:  ACS Nano       Date:  2014-08-26       Impact factor: 15.881

7.  Modification of a designed amphipathic cell-penetrating peptide and its effect on solubility, secondary structure, and uptake efficiency.

Authors:  Mousa Jafari; D Nedra Karunaratne; Chad M Sweeting; P Chen
Journal:  Biochemistry       Date:  2013-05-07       Impact factor: 3.162

Review 8.  Targeted therapy for hepatocellular carcinoma.

Authors:  Hans Christian Spangenberg; Robert Thimme; Hubert E Blum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06-02       Impact factor: 46.802

Review 9.  Clinical implications of basic research in hepatocellular carcinoma.

Authors:  Renumathy Dhanasekaran; Sudhakar K Venkatesh; Michael S Torbenson; Lewis R Roberts
Journal:  J Hepatol       Date:  2015-10-09       Impact factor: 25.083

10.  Nanoparticle Delivered Human Biliverdin Reductase-Based Peptide Increases Glucose Uptake by Activating IRK/Akt/GSK3 Axis: The Peptide Is Effective in the Cell and Wild-Type and Diabetic Ob/Ob Mice.

Authors:  Peter E M Gibbs; Tihomir Miralem; Nicole Lerner-Marmarosh; Mahin D Maines
Journal:  J Diabetes Res       Date:  2016-05-17       Impact factor: 4.011

View more
  6 in total

Review 1.  Strategies for Precise Engineering and Conjugation of Antibody Targeted-nanoparticles for Cancer Therapy.

Authors:  Yuan-Yuan Guo; Lu Huang; Zhi-Ping Zhang; De-Hao Fu
Journal:  Curr Med Sci       Date:  2020-07-17

Review 2.  Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances.

Authors:  Khaled Mahmoud; Shady Swidan; Mohamed El-Nabarawi; Mahmoud Teaima
Journal:  J Nanobiotechnology       Date:  2022-03-05       Impact factor: 10.435

3.  Ultrasound-Targeted Microbubble Destruction-Mediated Downregulation of EZH2 Inhibits Stemness and Epithelial-Mesenchymal Transition of Liver Cancer Stem Cells.

Authors:  Jie Wu; Lulu Sun; Tingting Liu; Gang Dong
Journal:  Onco Targets Ther       Date:  2021-01-11       Impact factor: 4.147

4.  Application and Efficacy of Melatonin Elastic Liposomes in Photoaging Mice.

Authors:  Xueqin Hou; Xinyu Qiu; Yaping Wang; Shuangshuang Song; Yifan Cong; Jifu Hao
Journal:  Oxid Med Cell Longev       Date:  2022-03-08       Impact factor: 6.543

5.  METTL3-mediated maturation of miR-589-5p promotes the malignant development of liver cancer.

Authors:  Jie Liu; Kai Jiang
Journal:  J Cell Mol Med       Date:  2022-03-29       Impact factor: 5.295

Review 6.  Applications of Magnetic Particle Imaging in Biomedicine: Advancements and Prospects.

Authors:  Xue Yang; Guoqing Shao; Yanyan Zhang; Wei Wang; Yu Qi; Shuai Han; Hongjun Li
Journal:  Front Physiol       Date:  2022-07-01       Impact factor: 4.755

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.